1000519-40-3

Basic information

• Product Name: 3-(4-(trifluoromethoxy)phenyl)propan-1-ol
• Synonyms: 3-(4-(trifluoromethoxy)phenyl)propan-1-ol;TERT-BUTYL N-(1-OXOBUTAN-2-YL)CARBAMATE
• CAS NO: 1000519-40-3
• Molecular Formula: C₁₀H₁₁F₃O₂
• Molecular Weight: 220.1883496
• Mol File: 1000519-40-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-(trifluoromethoxy)phenyl)propan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-(trifluoromethoxy)phenyl)propan-1-ol(1000519-40-3)
• EPA Substance Registry System: 3-(4-(trifluoromethoxy)phenyl)propan-1-ol(1000519-40-3)

Safety Data

• Hazardous Substances Data: 1000519-40-3(Hazardous Substances Data)

Usage

General Description

3-(4-(trifluoromethoxy)phenyl)propan-1-ol is an organic compound with a molecular formula C10H11F3O2. It is a colorless liquid with a slightly sweet odor and is commonly used in the synthesis of pharmaceuticals and agrochemicals. 3-(4-(trifluoromethoxy)phenyl)propan-1-ol is also known for its potential use as a building block in the production of various other compounds. It is important to handle this chemical with care and use it in a well-ventilated area due to its potential for causing respiratory irritation and other health hazards.

Upstream product

• 886499-74-7 3-[4-(trifluoromethoxy)phenyl]propanoic acid 
• 893642-04-1 3-(4-(trifluoromethoxy)phenyl)prop-2-yn-1-ol 
• 1129693-44-2 3-(4-trifluoromethoxyphenyl)prop-2-en-1-ol 

Downstream Products

• 1036396-43-6 3-(4-trifluoromethoxyphenyl)propionaldehyde 
• 1093172-94-1 1-(3-bromopropyl)-4- (trifluoromethoxy)benzene 
• 1333171-23-5 1-(3-iodopropyl)-4-trifluoromethoxybenzene 
• 1333170-20-9 (6S)-2-nitro-6-{3-[4-trifluoromethoxyphenyl]propoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 

Relevant articles and documents

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(–)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM3R). Compared to 1 and 5, (R)-(–)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(–)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(–)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

Structure-activity relationships of antitubercular nitroimidazoles. 2. determinants of aerobic activity and quantitative structure-activity relationships

The (S)-2-nitro-6-substituted 6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines have been extensively explored for their potential use as new antituberculars based on their excellent bactericidal properties on aerobic whole cells of Mycobacterium tuberculosis. A